nodular melanoma
Jump to navigation
Jump to search
Introduction
Second most common of tumors that arise in melanocytes of individuals with white skin.
Etiology
(risk factors)
- precursor lesions
- family history of melanoma
- light skin color with inability to tan
- excessive sun exposure, especially during preadolescence
- HCTZ (RR=1.2)[4]
Epidemiology
- median age 40-50 years
- equal incidence in males & females
- occurs in all races
- 15-30% of melanomas in US
- 8 times more common than superficial-spreading melanoma in Japanese
- responsible for most melanoma deaths
Pathology
- arises in the dermal-epidermal junction
- extends vertically into the dermis
- epidermal growth limited to a small groups of tumor cells also invading the dermis
- surrounding epidermis is normal
- tumor may show large epithelioid cells, spindle cells, small malignant melanocytes or mixtures of the 3
- S100 & HMB-45 positive
- the tumor is in the vertical growth phase from the onset
- most aggressive form of cutaneous melanoma[3]
Clinical manifestations
- uniformly elevated nodule or ulcerated thick plaque
- may be reddish-blue (purple) or blue-black; either uniform in color or mixed with brown or black
- may become polypoid & amelanocytic (pink) or tan
- early lesions are 1-3 cm, but may grow much larger if undetected initially
- oval or round with regular borders in contrast to other melanomas
- distribution: upper back (most common), legs, anterior trunk (same as superficial spreading melanoma), on arms & legs in Japanese
- arises within 2-4 months to 2 years from normal-appearing skin or a melanocytic nevus
Laboratory
- excisional biopsy with narrow margins
- punch biopsy is acceptable when total excision is not feasible or impractical
Complications
Differential diagnosis
- hemangioma: red or pink, can be blue or purple, slow growth
- pyogenic granuloma
- pigmented basal cell carcinoma
- rolled, pearly, translucent borders, arborizing telangiectasias
- dermoscopy distinguishes clinically
- keratoacanthoma
Management
(same for superficial spreading & acral melanoma):
- examine regional lymph nodes
- surgical excisions
- melanoma in situ
- excise with > 5mm margin
- thickness < 1 mm
- excise with 10 mm margin
- excise down to fascia or muscle if no underlying fasica
- direct closure without graft often possible
- node dissection only if palpable & suspscious for metastasis
- thickness 1-4 mm
- excision with 20 mm margin
- excise down to fascia or muscle if no underlying fasica
- regional lymphadenectomy if sentinel node procedure is positive
- lymph node dissection if regional lymph nodes are palpable
- thickness > 4 mm
- excision with 30 mm margin
- excise down to fascia or muscle if no underlying fasica
- lymph node dissection if regional lymph nodes are palpable
- melanoma in situ
- adjuvant chemotherapy
More general terms
Additional terms
References
- ↑ Color Atlas & Synopsis of Clinical Dermatology, Common & Serious Diseases, 3rd ed, Fitzpatrick et al, McGraw Hill, NY, 1997, pg 202-203
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 544
- ↑ 3.0 3.1 3.2 Mar V et al. Nodular melanoma: A distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol 2012 Nov 21 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23182058
- ↑ 4.0 4.1 Pottegard A, Pedersen SA, Schmidt SAJ et al Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma. JAMA Intern Med. Published online May 29, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29813157 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2682616